4,4'-(4-Hydroxybenzylazanediyl)diphenol | 1075742-54-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4,4'-(4-Hydroxybenzylazanediyl)diphenol
• 英文别名: 4-[(4-hydroxy-N-(4-hydroxyphenyl)anilino)methyl]phenol
• CAS: 1075742-54-9
• 化学式: C₁₉H₁₇NO₃
• 分子量: 307.349
• InChiKey: CWSPUZWISVKRNJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  63.9
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-hydroxy-N,N-bis-(4-hydroxyphenyl)-benzamide 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 以58%的产率得到4,4'-(4-Hydroxybenzylazanediyl)diphenol
  参考文献：
  名称：

  Promising core structure for nuclear receptor ligands: Design and synthesis of novel estrogen receptor ligands based on diphenylamine skeleton

  摘要：

  Novel diphenylamine-type estrogen receptor ligands were designed and synthesized, and their biological activities were evaluated by means of binding assays for estrogen receptor-alpha and -beta and cell proliferation assay using MCF-7 cells. Compounds 4f, 11b, 12c, and 8 showed moderate estrogenic activities. We propose that the diphenylamine skeleton may be a privileged structure for various nuclear receptor ligands, including RAR, RXR, and AR ligands. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.08.004

文献信息

• ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF
  申请人：GTX

  公开号：US20140057946A1

  公开（公告）日：2014-02-27

  The present invention relates to methods for reducing testosterone levels by reduction of luteinizing hormone (LH) or independent of LH levels in a male subject and methods of treating, suppressing, reducing the incidence, reducing the severity, or inhibiting prostate cancer, advanced prostate cancer, castration resistant prostate cancer (CRPC), metastatic castration resistant prostate cancer (mCRPC) and palliative treatment of prostate cancer, advanced prostate cancer, castration resistant prostate cancer (CRPC) and metastatic castration resistant prostate cancer (mCRPC), and methods of reducing high or increasing PSA levels and/or increasing SHBG levels in a subject suffering from prostate cancer, advanced prostate cancer, castration resistant prostate cancer (CRPC) and metastatic castration resistant prostate cancer (mCRPC). The compounds of this invention suppress free or total testosterone levels despite castrate levels secondary to ADT and reduce high or increasing PSA levels. This reduction in testosterone levels may be used to treat prostate cancer, advanced prostate cancer, CRPC and mCRPC without causing bone loss, decreased bone mineral density, increased risk of bone fractures, increased body fat, hot flashes and/or gynecomastia.

  本发明涉及一种通过降低雄激素水平的方法来降低雄性受试者中黄体生成素（LH）或独立于LH水平的方法，并且涉及一种用于治疗、抑制、减少发病率、减轻病情或抑制前列腺癌、晚期前列腺癌、去势抵抗性前列腺癌（CRPC）、转移性去势抵抗性前列腺癌（mCRPC）和前列腺癌、晚期前列腺癌、去势抵抗性前列腺癌（CRPC）和转移性去势抵抗性前列腺癌（mCRPC）的姿势，以及用于降低患有前列腺癌、晚期前列腺癌、去势抵抗性前列腺癌（CRPC）和转移性去势抵抗性前列腺癌（mCRPC）的受试者的高PSA水平或增加SHBG水平的方法。本发明的化合物可以抑制自由或总睾酮水平，尽管在ADT的情况下睾酮水平已经被去势，同时还可以降低高PSA水平或增加的PSA水平。这种降低睾酮水平的方法可以用于治疗前列腺癌、晚期前列腺癌、CRPC和mCRPC，而不会引起骨质流失、骨密度降低、骨折风险增加、体脂增加、潮热和/或乳腺增生。
• US9409856B2
  申请人：——

  公开号：US9409856B2

  公开（公告）日：2016-08-09
• Promising core structure for nuclear receptor ligands: Design and synthesis of novel estrogen receptor ligands based on diphenylamine skeleton
  作者：Kiminori Ohta、Yuki Chiba、Takumi Ogawa、Yasuyuki Endo

  DOI：10.1016/j.bmcl.2008.08.004

  日期：2008.9

  Novel diphenylamine-type estrogen receptor ligands were designed and synthesized, and their biological activities were evaluated by means of binding assays for estrogen receptor-alpha and -beta and cell proliferation assay using MCF-7 cells. Compounds 4f, 11b, 12c, and 8 showed moderate estrogenic activities. We propose that the diphenylamine skeleton may be a privileged structure for various nuclear receptor ligands, including RAR, RXR, and AR ligands. (C) 2008 Elsevier Ltd. All rights reserved.